Immunization prevention of HPV-associated neoplasias: S3 guidelines of the Working Committee of HPV Management Forum of Paul Ehrlich Society for Chemotherapy;Impfprävention HPV-assoziierter neoplasien: S3-leitlinie der Arbeitsgruppe HPV-Management-Forum der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V

Chemotherapie Journal

Volumn 17, Issue 4, 2008, Pages 120-171

  Pathirana, Delano ^a   Hillemanns, Peter ^a,b   Petry, Karl Ulrich ^a,c   Becker, Nikolaus ^d   Brockmeyer, Norbert H ^e   Erdmann, Ricardo ^a   Gissmann, Lutz ^a,d   Grundhewer, Herbert ^f   Ikenberg, Hans ^a,g   Kaufmann, Andreas M ^a   Klußmann, Jens Peter ^h   Kopp, Ina ⁱ   Pfister, Herbert ^a,j   Rzany, Berthold ^a   Schneede, Peter ^a,k   Schneider, Achim ^a   Smola, Sigrun ^a,j   Winter Koch, Nadja ^l   Wutzler, Peter ^m   Gross, Gerd ^a,n  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Klinikum Wolfsburg   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

^f Niedergelassener Arzt für Kinder und Jugendheilkunde   (Germany)

^g MVZ für Zytologie und Molekularbiologie Frankfurt GbR CytoMol   (Germany)

^h UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

ⁱ PHILIPPS UNIVERSITY MARBURG   (Germany)

^j UNIVERSITY OF COLOGNE   (Germany)

^k Klinikum Memmingen   (Germany)

^l Vulva CA Forum   (Germany)

^m JENA UNIVERSITY HOSPITAL   (Germany)

ⁿ UNIVERSITY OF ROSTOCK   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; WART VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANUS CARCINOMA; BRONCHOSPASM; COLPOSCOPY; CONDYLOMA ACUMINATUM; CRYOTHERAPY; ELECTROSTIMULATION THERAPY; GASTROENTERITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LARYNX PAPILLOMATOSIS; LOW LEVEL LASER THERAPY; NEOPLASM; OROPHARYNX CARCINOMA; PATHOGENESIS; PENIS CARCINOMA; POLYMERASE CHAIN REACTION; REVIEW; UTERINE CERVIX CARCINOMA IN SITU; VIROLOGY; VULVA CARCINOMA; WART VIRUS;

EID: 50149112638     PISSN: 09406735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Jahn I, Eberle A, Niehues C, Birn A, et al. Gesundheitsberichterstattung des Bundes, Gebärmuttererkrankungen. Heft 37. Robert Koch-Institut, 2007.
2. Cogliano V, Baan R, Straif K, Grosse Y, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005;6:204.
3. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005;32(Suppl 1):S16-24.
4. Bosch F, de Sanjosé S, Castellsagué X, Moreno V, et al. Epidemiology of human papillomavirus infections and associations with cervical cancer: New opportunities for prevention. In: Campo M (ed.). Papillomavirus research: From natural history to vaccines and beyond. Wymondham: Caister Academic Press, 2006:19-39.
5. Manhart LE, Holmes KK, Koutsky LA, Wood TR, et al. Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy. Sex Transm Dis 2006;33:502-8.
6. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. Lancet Infect Dis 2006;6:21-31.
7. Carter JJ, Koutsky LA, Wipf GC, Christensen ND, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996;174:927-36.
8. Klug SJ, Hukelmann M, Hollwitz B, Duzenli N, et al. Prevalence of human papillomavirus types in women screened by cytology in Germany. J Med Virol 2007;79:616-25.
9. Petry KU, Menton S, Menton M, van Loenen-Frosch F, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003;88:1570-7.
10. Schneider A, Hoyer H, Lotz B, Leistritza S, et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 2000;89:529-34.
11. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine 2006;24(Suppl 1):S1-15.
12. Ho GY, Bierman R, Beardsley L, Chang CJ, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
13. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 2001;358:1782-3.
14. Doorbar J. The papillomavirus life cycle. J Clin Virol 2005;32(Suppl 1); S7-15.
15. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 2004;68:362-72.
16. Durst M, Glitz D, Schneider A, zur Hausen H. Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization. Virology 1992;189:132-40.
17. Demeter LM, Stoler MH, Broker TR, Chow LT. Induction of proliferating cell nuclear antigen in differentiated keratinocytes of human papillomavirus infected lesions. Hum Pathol 1994;25:343-8.
18. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002;89:213-28.
19. Bohmer G, van den Brule AJ, Brummer O, Meijer CL, et al. No confirmed case of human papillomavirus DNA-negative cervical intraepithelial neoplasia grade 3 or invasive primary cancer of the uterine cervix among 511 patients. Am J Obstet Gynecol 2003;189:118-20.
20. Snijders PJ, van den Brule AJ, Meijer CJ. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 2003;201:1-6.
21. FUTURE II STUDY GROUP. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
22. Munoz N, Bosch FX, de Sanjose S, Herrero R, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
23. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
24. Statistisches Bundesamt. Gesundheitswesen, Todesursachen in Deutschland 2004. Fachserie 12/Reihe 4. Statistisches Bundesamt, 2005.
25. Richart RM. Natural history of cervical intraepithelial neoplasia. Clin Obstet Gynecol 1968;10:748-84.
26. Hampl M, Sarajuuri H, Wentzensen N, Bender HG, Kueppers V. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol 2006;108:1361-8.
27. Petty KU, Bohmer G, Iftner T, Davies P, et al. Factors associated with an increased risk of prevalent and incident grade III cervical intraepithelial neoplasia and invasive cervical cancer among women with Papanicolaou tests classified as grades I or II cervical intraepithelial neoplasia. Am J Obstet Gynecol 2002;186:28-34.
28. Creasman WT. Vaginal cancers. Curr Opin Obstet Gynecol 2005;17:71-6.
29. Cupp MR, Malek RS, Goellner JR, Smith TF, et al. The detection of human papillomavirus desoxyribonucleic acid in intraepithelial, in situ, verrucous and invasive carcinoma of the penis. J Urol 1995;154:1024-9.
30. Dillner J, Meijer CJ, von Krogh G, Horenblas S. Epidemiology of human papillomavirus infection. Scand J Urol Nephrol Suppl 2000;205:194-200.
31. Rubin MA, Kleter B, Zhou M, Ayala G, et al. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol 2001;159:1211-8.
32. Frisch M, Fenger C, van den Brule AJ, Sorensen P, et al. Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomaviruses. Cancer Res 1999;59:753-7.
33. Fox PA. Human papillomavirus and anal intraepithelial neoplasia. Curr Opin Infect Dis 2006;19:62-6.
34. Gross G, Barrasso R. Human papillomavirus infection. A clinical atlas. Wiesbaden, Berlin: Ullstein-Mosby, 1997.
35. Gross G, Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol 2004;193:35-14.
36. Gross G, Ikenberg H, Gissmann L, Hagedorn M. Papillomavirus infection of the anogenital region: correlation between histology, clinical picture, and virus type. Proposal of a new nomenclature. J Invest Dermatol 1985;85:147-52.
37. Lacey CJ. Therapy for genital human papillomavirus-related disease. J Clin Virol 2005;32(Suppl 1):S82-90.
38. Gross G, Ikenberg H, Petry KU, Pfister H, et al. [Condyloma acuminata and other HPV-associated diseases of the genitals, anus and urethra). Hautarzt 2007;58:179-86.
39. Krogh von G, Lacey CJ, Gross G, Barrasso R, et al. European Course on HPV Associated Pathology (ECHPV), European Branch of the International Union against Sexually Transmitted Infection and the European Office of the World Health Organization. Int J STD AIDS 2001;12(Suppl 3):40-7.
40. Lowy DR, Howley PM. Papillomavirus replication. In: Knipe DM. Howley PM (eds.). Fields Virology. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:2231-64.
41. Armstrong LR, Preston EJ, Reichert M, Phillips DL, et al. Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin Infect Dis 2000;31:107-9.
42. Wiatrak BJ. Overview of recurrent respiratory papillomatosis. Curr Opin Otolaryngol Head Neck Surg 2003;11:433-41.
43. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467-75.
44. Herrero R, Castellsague X, Pawlita M, Lissowska J, et al. Human papillomavirus and oral cancer: the international agency for research on cancer multicenter study. J Natl Cancer Inst 2003;95:1772-83.
45. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-56.
46. Mork J, Lie AK, Glattre E, Hallmans G, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001;344:1125-31.
47. Smith EM, Ritchie JM, Summersgill KF, Hoffman HT, et al. Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst 2004;96:449-55.
48. Reimers N, Kasper HU, Weissenborn SJ, Stutzer H, et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 2007;120:1731-8.
49. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 2006;24:2606-11.
50. Smeets SJ, Hesselink AT, Speel EJ, Haesevoets A, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007;121:2465-72.
51. Becker N. Epidemiological aspects of cancer screening in Germany. J Cancer Res Clin Oncol 2003;129:691-702.
52. Hakama M, Miller AB, Day NE. Screening for cancer of the uterine cervix. Lyon: IARC Scientific Publications, 1986:76.
53. IARC. Cervix cancer screening. Lyon: IARC Handbooks of Cancer Prevention, 2005:10.
54. European Medicines Agency. Gardasil, European Public Assessment Report. EPARs for authorised medicinal products for human use 2006. Revision 4, published 07/09/07 online im Internet: URL:http://www.emea.europa.eu/humandocs/ Humans/EPAR/gardasil/gardasil.htm
55. Villa LL, Costa RL, Petta CA, Andrade RP, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
56. Block SL, Nolan T, Sattler C, Barr E, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006;118:2135-45.
57. Giannini SL, Hanon E, Moris P, Van Mechelen M, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006;24:5937-49.
58. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, et al. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995;69:3959-63.
59. Harper DM, Franco EL, Wheeler C, Ferris DG, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
60. Fife KH, Wheeler CM, Koutsky LA, Barr E, et al. Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. Vaccine 2004;22:2943-52.
61. Robert Koch-Institut. Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Impfung gegen humane Papillomaviren (HPV) für Mädchen von 12 bis 17 Jahren - Empfehlung und Begründung. Epidemiol Bull 2007:12.
62. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
63. Koutsky LA, Ault KA, Wheeler CM, Brown DR, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
64. Mao C, Koutsky LA, Ault KA, Wheeler CM, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107:18-27.
65. Paavonen J, Jenkins D, Bosch FX, Naud P, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70.
66. Villa LL, Costa RL, Petta CA, Andrade RP, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459-66.
67. Harper DM, Franco EL, Wheeler CM, Moscicki AB, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
68. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369:1693-702.
69. Giroglou T, Sapp M, Lane C, Fligge C, et al. Immunological analyses of human papillomavirus capsids. Vaccine 2001;19:1783-93.
70. Smith JF, Brownlow M, Brown M, Kowalski R, et al. Antibodies from women immunized with Gardasil® cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007;3:109-16.
71. MSD Sanofi Pasteur. Fachinformation Gardasil. August 2007 online im Internet: URL: http://www.fachinfo.de/data/fi/jsearch?praep
72. GlaxoSmithKline. Fachinformation Cervarix. September 2007 online im Internet: URL: http://www.fachinfo.de/data/fi/jsearch?praep
73. Petry KU, Hillemanns P, Giesekmg F, Littlewood KJ, et al. Direkte und indirekte Kostenbewertungen HPV-assoziierter Erkrankungen (Genitalwarzen und zervikale Läsionen ) in Deutschland. 15. Jahrestagung der Deutschen Gesellschaft für Pädiatrische Infektiologie, Basel, 2007:Poster P68.
74. Hillemanns P, Petry KU, McAllister R, Busch K, et al. Vortrag zur HPV (6, 11, 16 & 18)-Impfung als Primärprävention bei HPV-bedingten Erkrankungen - eine Kosteneffektivitätsanalyse in Deutschland. (Informationsquelle: Sanofi MSD, 2007).
75. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-44.
76. Emeny RT, Wheeler CM, Jansen KU, Hunt WC, et al. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol 2002;76:7832-42.
77. Gross G. [Impact of prophylactic HPV vaccines on dermatology and venereology]. Hautarzt 2007;58:507-14.
78. Gieseking F. Incidence, prevalence and costs of treating genital warts in the pre-HPV vaccine era in Germany. Value Health 2005;8:64-5.
79. Kreuter A., Brockmeyer NH, Hochdorfer B, Weissenborn SJ, et al. Clinical spectrum and virologie characteristics of anal intraepithelial neoplasia in HIV infection. J Am Acad Dermatol 2005;52:603-8.
80. Roka S, Rasoul-Rockenschaub S, Roka J, Kirnbauer R, et al. Prevalence of anal HPV infection in solid-organ transplant patients prior to immunosuppression. Transpl Int 2004;17:366-9.
81. Busnach G, Piselli P, Arbustini E, Baccarani U, et al. Immunosuppression and cancer: A comparison of risks in recipients of organ transplants and in HIV-positive individuals. Transplant Proc 2006;38:3533-5.
82. European Medicines Agency. Cervarix, European Public Assessment Report, EPARs for authorised medicinal products for human use 2007. Published 03/10/2007 online im Internet: URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/ cervarix/cervarix.htm
83. Schwarz TF, Dubin GO. An AS 04-containing human papillomavirus (HPV) 16/18 vaccine for prevention of cervical cancer is immunogenic and well tolerated in women 15-55 years old. ACSO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2006;24(Suppl 18):56.
84. Hernan MA, Alonso A, Hernandez-Diaz S. Tetanus vaccination and risk of multiple sclerosis: a systematic review. Neurology 2006;67:212-5.
85. Gloster HM Jr., Roenigk RK. Risk of acquiring human papillomavirus from the plume produced by the carbon dioxide laser in the treatment of warts. J Am Acad Dermatol 1995;32:436-41.
86. Sawchuk WS, Weber PJ, Lowy DR, Dzubow LM. Infectious papillomavirus in the vapor of warts treated with carbon dioxide laser or electrocoagulation: detection and protection. J Am Acad Dermatol 1989;21:41-9.
87. Barrett WL, Garber SM. Surgical smoke: a review of the literature. Is this just a lot of hot air? Surg Endosc 2003;17:979-87.